Fig. 3.

The biomarkers change and underlying mechanisms of butaselen (BS) to prevent hepatocarcinogenesis. (A) Histoimmunochemical and immunoblotting analysis of glypican-3 (GPC3) and CD34. Serum level of (B) alpha-fetal protein (AFP), and (C) thioredoxin reductase (TrxR) activity at week 24. (D) Protein expression of TrxR and NF-κB pathway in liver of every group. (E) Gene and (F) protein level of inflammatory factors in mice liver. Data were shown as mean ± std, n ≥ 6 and analyzed with One-way ANOVA. *, ^#p < 0.05 compared with control or model group.